October 2011

FDA approves Roche’s hepatitis B test

Monday, October 31, 2011

Roche has reported that the FDA granted Premarket Approval (PMA) for its IgM antibody to hepatitis B core antigen (Anti-HBc IgM) assay for use on the cobas e 601 analyzer, the immunoassay module of the cobas 6000 analyzer series for mid-volume laboratories. The test represents the final component of the acute panel within the hepatitis test menu for the cobas 6000 series.

[Read More]

Revalesio’s first human asthma trial shows promising results

Monday, October 31, 2011

Revalesio has reported that in this first in man asthma study, RNS60 demonstrated therapeutic benefit and proved safe at all dose levels. In a multi-dose stage of the phase I study, RNS60 significantly improved peak flows and quality of life scores in patients diagnosed with stable, mild to moderate asthma. These findings demonstrate that RNS60, a novel product containing charge-stabilized nanostructures (CSN), is safe and has therapeutic benefit in human subjects suffering from asthma.

[Read More]

Taylor joins Bestnet as senior scientist

Monday, October 31, 2011

Bestnet has named Robert N. Taylor, Ph.D., senior scientist. In addition to a contributory role in the company’s product research & development efforts, Taylor’s activities will include participation in various scientific/technical working groups and representing Bestnet on scientific committees.

[Read More]

Oxford BioMedica, Mayo Clinic collaborate in glaucoma research

Monday, October 31, 2011

Oxford BioMedica has entered into a research and development collaboration with Mayo Clinic to develop a novel gene therapy for the treatment of chronic glaucoma. Under the terms of the agreement, Mayo Clinic and Oxford BioMedica will undertake pre-clinical studies to establish the feasibility of treating glaucoma using Oxford BioMedica’s proprietary LentiVector gene delivery technology expressing a COX-2 gene and a PGF-2alpha receptor gene in order to reduce intraocular pressure. The collaboration includes an option for exclusive US rights to license Mayo Clinic’s glaucoma technology, which Oxford BioMedica can exercise upon completion of pre-clinical studies under confidential terms agreed by Mayo Clinic and Oxford BioMedica.

[Read More]

BBK, PatientsLikeMe launch online diabetes movement

Friday, October 28, 2011

BBK Worldwide and PatientsLikeMe have launched CallingAllTypes.com, an online social health initiative for people with type 1 and type 2 diabetes. CallingAllTypes.com is a vehicle for people to share their experiences with diabetes. Within seconds of individuals posting their thoughts, social media outlets including Facebook, YouTube, and Twitter will pick up their words, creating instantaneous viral awareness – a dynamic way to inform the public, including policy makers and health professionals, about the real toll diabetes takes on individuals and families. CallingAllTypes.com will donate $1 to the Atlanta chapter of the American Diabetes Association for each of the first 10,000 visitors who help to create the needed awareness about this condition by posting a comment during the month of November.

[Read More]

Southern Research names directors

Friday, October 28, 2011

Southern Research Institute have reported that Damon Papac, Ph.D., and Joseph Murphy, Ph.D. have joined the Birmingham, Ala.-based not-for-profit research organization to lead two key departments within its drug development division, a technology group that primarily provides contract preclinical drug development services for the pharmaceutical industry and government clients.

[Read More]